<DOC>
	<DOCNO>NCT00118924</DOCNO>
	<brief_summary>Tick-borne encephalitis ( TBE ) viral illness common Northern Hemisphere , especially Europe Asia . TBE infection may lead central nervous system problem death . The purpose study test safety immune response TBE vaccine healthy adult . The vaccine relate live attenuate virus develop dengue virus infection .</brief_summary>
	<brief_title>Safety Immune Response Tick-Borne Encephalitis Vaccine ( LGT ( TP21 ) /DEN4 ) Healthy Adults</brief_title>
	<detailed_description>TBE common illness Europe Asia , usually associate mild illness sometimes lead long-term symptom even death . This study evaluate safety immunogenicity live attenuate chimeric virus , LGT ( TP21 ) /DEN4 , derive Langat flavivirus DEN4 dengue virus serotypes . Each volunteer involve study 180 day . Participants Cohort 1 randomly assign receive LGT ( TP21 ) /DEN4 placebo study entry . Cohort 2 begin safety review participant Cohort 1 . Participants Cohort 2 receive high dose LGT ( TP21 ) /DEN4 placebo . After vaccination , participant ask monitor temperature every day 16 day Day 19 . Study visit occur every day vaccination Day 16 , follow 5 additional visit select day Day 180 . Blood collection target physical exam occur study visit . Some participant ask undergo skin biopsy additional blood collection select visit .</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Tick-Borne</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Willing available follow duration study Willing use acceptable mean contraception Good general health Pregnancy breastfeed Clinically significant neurologic , heart , lung , liver , rheumatologic , autoimmune , kidney disease Behavioral , cognitive , psychiatric disease , opinion investigator , affect ability volunteer understand cooperate study Blood disease History migraine headache History encephalitis Alcohol drug use cause medical , occupational , family problem within 12 month prior study entry History severe allergic reaction anaphylaxis Emergency room visit hospitalization severe asthma within 6 month prior study entry HIV1 infect Hepatitis C virus infect Hepatitis B surface antigen positive Known immunodeficiency syndrome Use corticosteroid immunosuppressive drug within 30 day prior study entry . Participants use topical nasal corticosteroid exclude . Live vaccine within 4 week prior study entry Killed vaccine within 2 week prior study entry Blood product within 6 month prior study entry Investigational drug vaccine within 3 month prior study entry Previously receive licensed experimental yellow fever , tickborne encephalitis , dengue vaccine Surgical removal spleen History tickborne encephalitis History dengue virus infection flavivirus infection ( e.g. , yellow fever virus , St. Louis encephalitis , West Nile virus , Japanese encephalitis virus ) Other condition , opinion investigator , would affect participant 's participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Dengue Vaccine</keyword>
	<keyword>Tick-Borne Illnesses</keyword>
	<keyword>Flavivirus</keyword>
</DOC>